Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Adjuvant Therapy for High-Risk Renal Cell Carcinoma
James L. Liu
, Mohamad E. Allaf
, Michael A. Gorin
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjuvant Therapy for High-Risk Renal Cell Carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjuvant Therapy
100%
High Risk
100%
Renal Cell Carcinoma
100%
Clinical Trials
20%
Disease Progression
20%
Standard of Care
20%
Cancer Mortality
20%
Surgical Resection
20%
Disease Risk
20%
Clinical Benefit
20%
Disease-free Survival
20%
Number of Trials
20%
Survival Benefit
20%
Hormonal Therapy
20%
Tyrosine Kinase Inhibitor
20%
Immune Checkpoint Inhibitors
20%
Cancer Vaccine
20%
Surgical Extirpation
20%
Postoperative Therapy
20%
Localized Renal Cell Carcinoma
20%
Cytokine Immunotherapy
20%
Locally Advanced Renal Cell Carcinoma
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Cytokine
100%
Tyrosine Kinase Inhibitor
100%
Cancer Immunotherapy
100%
Disease Free Survival
100%
Immune Checkpoint Inhibitor
100%
Medicine and Dentistry
Adjuvant Therapy
100%
Clear Cell Renal Cell Carcinoma
100%
Malignant Neoplasm
25%
Disease Exacerbation
25%
Clinical Trial
25%
Hormone Therapy
25%
Tyrosine-Kinase Inhibitor
25%
Disease Free Survival
25%
Immune Checkpoint Inhibitor
25%
Postoperative Care
25%
Tumor Vaccine
25%
Cytokine Immunotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Malignant Neoplasm
33%
Disease Exacerbation
33%
Cytokine
33%
Immunotherapy
33%
Clinical Trial
33%
Protein Tyrosine Kinase Inhibitor
33%
Disease Free Survival
33%
Hormone Cancer Therapy
33%
Immune Checkpoint Inhibitor
33%
Tumor Vaccine
33%